Health and economic impact of rotavirus vaccination in GAVI-eligible countries

Kim, Sun-Young; Sweet, Steve; Slichter, David; Goldie, Sue J

doi:10.1186/1471-2458-10-253

BMC Public Health

Table 2 Implied coverage rates for a base-case scale-up scenario (%)

From: Health and economic impact of rotavirus vaccination in GAVI-eligible countries

Country	Category^a	Year 1	Year 2	Year 3	Year 4	Year 5	Year 6	Year 7	Year 8	Year 9	Year 10
		2010	2011	2012	2013	2014	2015	2016	2017	2018	2019
AFR D
Angola	10										31.0
Benin	5					15.0	30.6	46.2	61.8	77.4	93.0
Burkina Faso	5					57.0	65.4	73.8	82.2	90.6	99.0
Cameroon	3			53.0	60.8	68.5	76.3	84.0	84.0	84.0	84.0
Chad	8								28.0	30.5	33.0
Comoros	7							27.0	36.0	45.0	54.0
Ghana	6						80.0	81.4	82.8	84.2	85.6
Guinea	8								57.0	59.2	61.3
Guinea-Bissau	9									47.0	51.6
Liberia	5					48.0	56.8	65.6	74.4	83.2	92.0
Madagascar	6						61.0	66.4	71.8	77.2	82.6
Mali	5					54.0	63.0	72.0	81.0	90.0	99.0
Mauritania	8								31.0	38.2	45.3
Niger	9									25.0	34.1
Nigeria	4				41.0	44.2	47.4	50.6	53.8	57.0	57.0
Sao Tome	3			43.0	57.0	71.0	85.0	99.0	99.0	99.0	99.0
Senegal	6						54.0	60.8	67.6	74.4	81.2
Sierra Leone	6						24.0	36.6	49.2	61.8	74.4
The Gambia	5					84.0	86.4	88.8	91.2	93.6	96.0
Togo	6						50.0	57.8	65.6	73.4	81.2
AFR E
Burundi	10										74.0
Central African Republic	10										29.0
Congo	10										33.0
Cote d'Ivoire	4				10.0	22.8	35.6	48.4	61.2	74.0	74.0
Democratic Republic of the Congo	10										40.0
Eritrea	6						52.0	58.6	65.2	71.8	78.4
Ethiopia	6						42.0	49.8	57.6	65.4	73.2
Kenya	6						72.0	74.6	77.2	79.8	82.4
Lesotho	3			14.0	33.3	52.5	71.8	91.0	91.0	91.0	91.0
Malawi	5					64.0	69.4	74.8	80.2	85.6	91.0
Mozambique	8								25.0	34.2	43.3
Rwanda	5					88.0	89.8	91.6	93.4	95.2	97.0
Tanzania	7							79.0	79.8	80.7	81.5
Uganda	8								29.0	37.3	45.7
Zambia	5					80.0	83.0	86.0	89.0	92.0	95.0
Zimbabwe	8								9.0	20.0	31.0
AMR A, B & D
Cuba	1	93.0	95.0	97.0	99.0	99.0	99.0	99.0	99.0	99.0	99.0
Guyana	1	89.0	93.0	93.0	93.0	93.0	93.0	93.0	93.0	93.0	93.0
Honduras	1	84.0	93.0	93.0	93.0	93.0	93.0	93.0	93.0	93.0	93.0
Bolivia	1	82.0	83.0	83.0	83.0	83.0	83.0	83.0	83.0	83.0	83.0
Haiti	10										39.0
Nicaragua	1^b	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0
EMR D
Afghanistan	10										31.0
Djibouti	2		46.0	56.8	67.5	78.3	89.0	89.0	89.0	89.0	89.0
Pakistan	4				63.0	65.0	67.0	69.0	71.0	73.0	73.0
Somalia	9									33.0	32.7
Sudan	3			22.0	39.8	57.5	75.3	93.0	93.0	93.0	93.0
Yemen	6						9.0	24.6	40.2	55.8	71.4
EUR B & C
Armenia	1	55.0	66.3	77.7	89.0	89.0	89.0	89.0	89.0	89.0	89.0
Azerbaijan	1	95.0	95.0	95.0	95.0	95.0	95.0	95.0	95.0	95.0	95.0
Georgia	1	55.0	67.3	79.7	92.0	92.0	92.0	92.0	92.0	92.0	92.0
Kyrgyzstan	1	10.0	38.3	66.7	95.0	95.0	95.0	95.0	95.0	95.0	95.0
Tajikistan	1	39.0	54.7	70.3	86.0	86.0	86.0	86.0	86.0	86.0	86.0
Uzbekistan	1	5.0	36.0	67.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0
Moldova	1	81.0	85.7	90.3	95.0	95.0	95.0	95.0	95. 0	95.0	95.0
Ukraine	1	4.0	32.7	61.3	90.0	90.0	90.0	90.0	90.0	90.0	90.0
SEAR B & D
Indonesia	4				42.0	49.0	56.0	63.0	70.0	77.0	77.0
Korea, Democratic Republic	10										27.0
Sri Lanka	3			62.0	71.0	80.0	89.0	98.0	98.0	98.0	98.0
Timor Leste	4				57.0	61.4	65.8	70.2	74.6	79.0	79.0
Bangladesh	7							5.0	18.7	32.3	46.0
Bhutan	3			90.0	91.5	93.0	94.5	96.0	96.0	96.0	96.0
India	3			6.0	25.5	45.0	64.5	84.0	84.0	84.0	84.0
Myanmar	7							8.0	20.8	33.7	46.5
Nepal	7							2.0	15.3	28.7	42. 0
WPR B
Cambodia	5					50.0	58.2	66.4	74.6	82.8	91.0
Kiribati	2		36.0	47.5	59.0	70.5	82.0	82.0	82.0	82.0	82.0
Lao People Democratic Republic	8								50.0	51.8	53.7
Mongolia	2		95.0	95.3	95.5	95.8	96.0	96.0	96.0	96.0	96.0
Papua New Guinea	4				60.0	58.4	56.8	55.2	53.6	52.0	52.0
Solomon Islands	2		53.0	59.3	65.5	71.8	78.0	78.0	78.0	78.0	78.0
Viet Nam	5					78.0	81.0	84.0	87.0	90.0	93.0

a The profile of each category is as follows:
Category 1: 13 countries classified by Atherly et al.'s demand forecasting study [36] as "Phase 1" countries that are likely to introduce rotavirus vaccines earlier than other countries.
Category 2: Lower middle per capita income ($976-3,705) and introduction of both Hib and HepB vaccines.
Category 3: Lower middle per capita income ($976-3,705), either Hib or HepB vaccine introduction, and high (>80%) to very high (>90%) DTP3 coverage.
Category 4: Lower middle per capita income ($976-3,705), either Hib or HepB vaccine introduction, and low (<70%) to moderate (>70%) DTP3 coverage.
Category 5: Low income (<$975), Hib or HepB vaccine introduction, and very high (>90%) DTP3 coverage.
Category 6: Low income (<$975), both Hib and HepB vaccine introduction, and high (>80%) DTP3 coverage.
Category 7: Low income (<$975), either Hib or HepB vaccine introduction, and high (>80%) DTP3 coverage.
Category 8: Low income (<$975), either Hib or HepB vaccine introduction, and low (<70%) to moderate (>70%) DTP3 coverage.
Category 9: Low income (<$975), neither Hib nor HepB vaccine introduction.
Category 10: 8 countries judged by Atherly et al. [36] to be countries that are not likely to introduce rotavirus vaccines.
b Introduced rotavirus vaccine in 2006.

Back to article page

ISSN: 1471-2458

Contact us

Submission enquiries: bmcpublichealth@biomedcentral.com
General enquiries: ORSupport@springernature.com